ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024

18 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

04 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Conferences

28 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

23 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

08 1 2024 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

04 1 2024 08:55:49 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration

27 12 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

20 11 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

07 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ET

31 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

19 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

10 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

05 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

02 10 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

20 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

09 9 2023 20:00:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

05 9 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

31 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

14 8 2023 07:30:00 提供 Nasdaq GlobeNewswire